Literature DB >> 22753941

Cutting edge: CTLA-4 on effector T cells inhibits in trans.

Emily Corse1, James P Allison.   

Abstract

CTLA-4 is thought to inhibit effector T cells both intrinsically, by competing with CD28 for B7 ligands, and extrinsically, through the action of regulatory T cells (Tregs). We studied in vivo responses of normal and CTLA-4-deficient Ag-specific murine effector CD4(+) T cells. We directly demonstrate that effector T cell-restricted CTLA-4 inhibits T cell responses in a cell-extrinsic manner. Cotransfer experiments show that CTLA-4 on normal effector CD4(+) T cells completely abrogates the dramatically increased expansion normally experienced by their CTLA-4-deficient counterparts. Neither the wild-type nor the CTLA-4-deficient T cells express the Treg transcription factor Foxp3 when transferred alone or together. Thus, cell-extrinsic inhibition of T cell responses by CTLA-4 is not limited to Tregs but is also a function of effector T cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22753941     DOI: 10.4049/jimmunol.1200695

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  51 in total

1.  Analysis of Programmed Death-1 in Patients with Psoriatic Arthritis.

Authors:  Michael Peled; Marianne Strazza; Inbar Azoulay-Alfaguter; Gregg J Silverman; Jose U Scher; Adam Mor
Journal:  Inflammation       Date:  2015-08       Impact factor: 4.092

Review 2.  T-cell costimulatory blockade in organ transplantation.

Authors:  Jonathan S Maltzman; Laurence A Turka
Journal:  Cold Spring Harb Perspect Med       Date:  2013-12-01       Impact factor: 6.915

3.  New inhibitory signaling by CTLA-4.

Authors:  Christoph Wülfing; Helen M Tunbridge; David C Wraith
Journal:  Nat Immunol       Date:  2014-05       Impact factor: 25.606

4.  Surface expression of inhibitory (CTLA-4) and stimulatory (OX40) receptors by CD4+ regulatory T cell subsets circulating in human malaria.

Authors:  Raquel M Gonçalves-Lopes; Nathália F Lima; Karina I Carvalho; Kézia K G Scopel; Esper G Kallás; Marcelo U Ferreira
Journal:  Microbes Infect       Date:  2016-06-16       Impact factor: 2.700

5.  Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.

Authors:  Udupi A Ramagopal; Weifeng Liu; Sarah C Garrett-Thomson; Jeffrey B Bonanno; Qingrong Yan; Mohan Srinivasan; Susan C Wong; Alasdair Bell; Shilpa Mankikar; Vangipuram S Rangan; Shrikant Deshpande; Alan J Korman; Steven C Almo
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-08       Impact factor: 11.205

6.  Treatment with retinoid X receptor agonist IRX4204 ameliorates experimental autoimmune encephalomyelitis.

Authors:  Roshantha As Chandraratna; Randolph J Noelle; Elizabeth C Nowak
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

7.  CTLA-4 expressed by FOXP3+ regulatory T cells prevents inflammatory tissue attack and not T-cell priming in arthritis.

Authors:  Katrin Klocke; Rikard Holmdahl; Kajsa Wing
Journal:  Immunology       Date:  2017-06-20       Impact factor: 7.397

Review 8.  Braking bad: novel mechanisms of CTLA-4 inhibition of T cell responses.

Authors:  S M Krummey; M L Ford
Journal:  Am J Transplant       Date:  2014-11-11       Impact factor: 8.086

9.  The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells.

Authors:  Peter T Sage; Alison M Paterson; Scott B Lovitch; Arlene H Sharpe
Journal:  Immunity       Date:  2014-12-05       Impact factor: 31.745

Review 10.  Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.

Authors:  Frank A Schildberg; Sarah R Klein; Gordon J Freeman; Arlene H Sharpe
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.